2 weeks ago
9
Soumya Eswaran
Thu, February 19, 2026 astatine 6:09 AM CST 3 min read
Meridian Funds, managed by ArrowMark Partners, released its fourth-quarter 2025 capitalist missive for “Meridian Small Cap Growth Fund”. A transcript of the missive tin beryllium downloaded here. U.S. equity markets navigated a 4th supported by optimism astir imaginable monetary easing and caution regarding economical maturation and valuations. Early gains were driven by beardown AI-related net and the US Federal Reserve’s complaint chopped successful October, which improved expectations for fiscal conditions. However, marketplace sentiment cooled aboriginal successful the quarter. Despite this moderation, the 4th contributed positively to robust yearly results. Small caps delivered an yearly instrumentality of 12.8% with a 2.2% Q4 gain. Value outperformed maturation arsenic per the Russell household of indices. In Q4 2025, The Meridian Small Cap Growth Fund returned 0.90% (net) compared to the Russell 2000 Growth Index’s 1.22% return. In addition, delight cheque the Fund’s apical 5 holdings to cognize its champion picks successful 2025.
In its fourth-quarter 2025 capitalist letter, Meridian Small Cap Growth Fund highlighted stocks specified arsenic Zenas BioPharma, Inc. (NASDAQ:ZBIO). Zenas BioPharma, Inc. (NASDAQ:ZBIO) is simply a clinical-stage biopharmaceutical company. The one-month instrumentality of Zenas BioPharma, Inc. (NASDAQ:ZBIO) was 30.78%, and its shares gained 241.61% of their worth implicit the past 52 weeks. On February 18, 2026, Zenas BioPharma, Inc. (NASDAQ:ZBIO) banal closed astatine $26.68 per share, with a marketplace capitalization of $1.432 billion.
Meridian Small Cap Growth Fund stated the pursuing regarding Zenas BioPharma, Inc. (NASDAQ:ZBIO) successful its 4th fourth 2025 capitalist letter:
"Zenas BioPharma, Inc. (NASDAQ:ZBIO) is simply a clinical-stage planetary biopharmaceutical institution focused connected processing transformative therapies for patients with autoimmune diseases. Its pb drug, Obexelimab, is successful Phase 3 objective trials and, portion results are inactive pending, appears connected way for imaginable support and motorboat successful 2027. During the quarter, the banal exhibited beardown performance, buoyed by encouraging Phase II proceedings data. While we admit that near-term stock terms fluctuations successful clinical-stage companies often hinge connected idiosyncratic information releases, our absorption remains connected Zenas BioPharma's semipermanent gross potential. With aggregate indications successful development, determination is simply a imaginable of achieving yearly revenues exceeding $1 billion, contingent upon palmy improvement and regulatory approval."
Zenas BioPharma, Inc. (NASDAQ:ZBIO) is not connected our database of 30 Most Popular Stocks Among Hedge Funds. According to our database, 13 hedge money portfolios held Zenas BioPharma, Inc. (NASDAQ:ZBIO) astatine the extremity of the 3rd quarter, the aforesaid arsenic successful the erstwhile quarter. While we admit the imaginable of Zenas BioPharma, Inc. (NASDAQ:ZBIO) arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.
English (CA) · 
English (US) · 
Spanish (MX) ·